“For the first use case, we are investigating how melanoma tumors that fail to respond to treatment exploit the immune system. We think TDI will provide meaningful data to search for alternative therapeutic strategies and combination therapy opportunities.”
Xinghua Lu, PhD, University of Pittsburgh School of Medicine Department of Bioinfomatics.
“Tumors are highly heterogeneous in terms of their genomic drivers and their cell-signaling-pathway mechanisms; the better we can infer the specific mechanisms of a given tumor, the better we will be able to tailor precision therapies to treat that tumor.”
Greg Cooper, PhD, University of Pittsburgh School of Medicine Department of Bioinfomatics.